Evidence map›Paper›PMID 22981949›Full record

ReviewNeuropharmacology2013

The involvement of Reelin in neurodevelopmental disorders.

Timothy D Folsom, S Hossein Fatemi

Abstract readReview
In one paragraph

Review in Neuropharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
144citing papers in PubMed, 3 pooled it
12.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

144 citing papers in PubMed, 3 syntheses or guidelines pooled it, 274 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Drospondin, a glial glycoprotein with similarities to human Reelin/F-spondin, contributes toProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Landscape of intrinsically disordered proteins in mental disorder diseases.Computational and structural biotechnology journal · 2024
    Article

84 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Timothy D FolsomDepartment of Psychiatry, Division of Neuroscience Research, University of Minnesota Medical School, 420 Delaware St. SE, MMC 392, Minneapolis, MN 55455, USA. folso013@umn.edu
S Hossein Fatemi
University of Minnesota Medical Center · US

Funding

GABAergic and Reelin Deficits in SchizophreniaR01MH086000 · NIMH · UNIVERSITY OF MINNESOTA · PI FATEMI, SEYYED HOSSEIN · 2010 to 2014
$1.7M
GABAergic Dysfunction in AutismR01HD052074 · NICHD · UNIVERSITY OF MINNESOTA · PI FATEMI, SEYYED HOSSEIN · 2007 to 2011
$1.5M
NICHD NIH HHS 5R01HD052074-01A2NICHD NIH HHS R01 HD052074NIMH NIH HHS 5R01MH086000-01A2NIMH NIH HHS R01 MH086000
6 · The paper itself

Abstract

Reelin is a glycoprotein that serves important roles both during development (regulation of neuronal migration and brain lamination) and in adulthood (maintenance of synaptic function). A number of neuropsychiatric disorders including autism, schizophrenia, bipolar disorder, major depression, Alzheimer's disease and lissencephaly share a common feature of abnormal Reelin expression in the brain. Altered Reelin expression has been hypothesized to impair neuronal connectivity and synaptic plasticity, leading ultimately to the cognitive deficits present in these disorders. The mechanisms for abnormal Reelin expression in some of these disorders are currently unknown although possible explanations include early developmental insults, mutations, hypermethylation of the promoter for the Reelin gene (RELN), miRNA silencing of Reelin mRNA, FMRP underexpression and Reelin processing abnormalities. Increasing Reelin expression through pharmacological therapies may help ameliorate symptoms resulting from Reelin deficits. This article is part of the Special Issue entitled 'Neurodevelopmental Disorders'.

Indexed as

Autistic DisorderBrainCell Adhesion Molecules, NeuronalCognitionExtracellular Matrix ProteinsHumansNerve Tissue ProteinsReceptors, Cell SurfaceReelin ProteinSchizophreniaSerine EndopeptidasesCell Adhesion Molecules, NeuronalExtracellular Matrix ProteinsNerve Tissue ProteinsReceptors, Cell SurfaceReelin Proteinreelin receptorRELN protein, humanSerine Endopeptidases

Identifiers

PMID22981949
PMCPMC3632377
OpenAlexW2151812654

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.